List of Excipients in Branded Drug MYRBETRIQ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Astellas Pharma US Inc	MYRBETRIQ	mirabegron	0469-2601	BUTYLATED HYDROXYTOLUENE
Astellas Pharma US Inc	MYRBETRIQ	mirabegron	0469-2601	FERRIC OXIDE RED
Astellas Pharma US Inc	MYRBETRIQ	mirabegron	0469-2601	FERRIC OXIDE YELLOW
Astellas Pharma US Inc	MYRBETRIQ	mirabegron	0469-2601	HYDROXYPROPYL CELLULOSE
Astellas Pharma US Inc	MYRBETRIQ	mirabegron	0469-2601	HYPROMELLOSE 2910

Myrbetriq Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Myrbetriq, the brand name for mirabegron, uses a conventional oral extended-release platform built around a hydrophilic polymer matrix. Its strongest excipient opportunities are not direct substitution of the active ingredient, but development of bioequivalent extended-release tablets, pediatric granules, taste-masked suspensions, and manufacturing systems that reduce formulation cost while preserving release performance. Because mirabegron is a small molecule, generic applicants face ANDA requirements rather than biosimilar development standards. The commercial opportunity is concentrated in formulation replication, excipient supply, pediatric delivery, and differentiated generic or authorized-generic products.

What formulation does Myrbetriq use?

Myrbetriq is marketed primarily as a once-daily extended-release tablet containing 25 mg or 50 mg of mirabegron. The product is approved for overactive bladder and, in specified patients, neurogenic detrusor overactivity associated with multiple sclerosis or spinal cord injury. Myrbetriq Granules for oral suspension provides an alternative for pediatric patients who cannot swallow tablets.

The tablet formulation depends on a controlled-release matrix rather than an osmotic pump or multiparticulate capsule. The US prescribing information identifies excipients including polyethylene oxide, hypromellose, macrogol, magnesium stearate, colloidal silicon dioxide, ferric oxide colorants, and other processing or coating materials, depending on the dosage form and strength.[1]

Product	Active ingredient	Dosage form	Release profile	Primary excipient opportunity
Myrbetriq 25 mg	Mirabegron	Extended-release tablet	Once daily	Hydrophilic matrix replication and coating
Myrbetriq 50 mg	Mirabegron	Extended-release tablet	Once daily	Polymer ratio, compression, and dissolution control
Myrbetriq Granules	Mirabegron	Granules for oral suspension	Once daily after reconstitution	Taste masking, suspension stability, and pediatric dosing

The commercial objective for a generic developer is not to reproduce every excipient identically. FDA approval generally permits qualitative and quantitative excipient differences if the product meets pharmaceutical equivalence, bioequivalence, quality, and performance requirements.[2]

Which excipients are commercially important in Myrbetriq?

Polyethylene oxide and hypromellose

Polyethylene oxide is likely the central release-controlling material in the tablet matrix. It hydrates after administration, forms a viscous gel layer, and controls diffusion and erosion of mirabegron. Hypromellose can provide additional matrix structure and tablet integrity.

For excipient suppliers, the opportunity is specification-driven rather than commodity-driven. Relevant attributes include:

• Polymer molecular weight and viscosity
• Particle-size distribution
• Hydration rate
• Moisture content
• Batch-to-batch gel strength
• Compatibility with direct compression
• Impact on dissolution across pH conditions

A generic manufacturer can use a different grade or combination of polymers, but that change may alter the dissolution curve. The commercial value therefore lies in high-consistency pharmaceutical grades and technical support that shortens formulation development.

Macrogol and film-coating materials

Macrogol, also known as polyethylene glycol, is commonly used as a plasticizer or coating component. Coating excipients can affect tablet appearance, swallowing characteristics, moisture protection, and mechanical durability.

A coating supplier could pursue a lower-cost or lower-moisture system that maintains:

• Weight gain
• Film uniformity
• Color matching
• Tablet stability
• Resistance to abrasion
• Compatibility with extended-release dissolution

Colorants, including ferric oxide pigments, are commercially relevant because dosage-strength differentiation reduces dispensing errors. A colorant substitution may require comparative stability and visual identification work even when it does not change release performance.

Lubricants and glidants

Magnesium stearate and colloidal silicon dioxide support powder flow, die filling, ejection, and manufacturing consistency. Their concentrations must be controlled because excessive magnesium stearate can reduce tablet wettability and slow dissolution. Colloidal silicon dioxide can improve flow but may affect blend uniformity and compression behavior.

A lower-cost excipient strategy should prioritize process robustness rather than simply replacing the incumbent materials. The formulation must maintain content uniformity at a relatively low drug load, particularly for the 25 mg strength.

What excipient strategy is required for a generic Myrbetriq tablet?

A generic tablet developer should treat the product as a critical-quality-attribute problem. The most sensitive variables are polymer grade, polymer concentration, tablet hardness, porosity, compression force, coating weight, and dissolution testing conditions.

Recommended development sequence

1. Establish the reference product's dissolution profile across multiple media and agitation conditions.
2. Characterize tablet dimensions, hardness, friability, density, and disintegration behavior.
3. Screen polyethylene oxide and hypromellose grades with different viscosity profiles.
4. Optimize granulation or direct-compression conditions.
5. Match release behavior under fed and fasted conditions.
6. Confirm stability under accelerated and long-term storage.
7. Select an excipient composition that avoids unnecessary dependence on a protected formulation claim.

A successful design-around may use a different polymer combination, a different granulation process, or a different coating architecture. The key regulatory issue is whether the resulting product has equivalent performance, not whether it uses the same inactive-ingredient list.

What patents protect Myrbetriq and its formulation?

The core mirabegron patent estate originated from Astellas and includes patent families directed to benzene derivatives and related pharmaceutical uses. A commonly cited US patent is US 8,129,343, assigned to Astellas Pharma Inc., covering benzene derivatives including mirabegron-related subject matter.[3]

Patent risk should be separated into four categories:

Patent category	Relevance to generic entry	Excipient impact
Compound patents	Protect mirabegron or related chemical subject matter	Usually high; may block active-ingredient entry
Formulation patents	Protect extended-release composition or delivery design	Directly relevant to polymer and coating selection
Method-of-use patents	Cover overactive bladder or neurogenic detrusor overactivity treatment	May require a Paragraph IV or skinny-label strategy
Manufacturing patents	Cover synthesis, purification, or solid-state processing	Can affect API sourcing and cost

The Orange Book is the controlling source for currently listed US patents and pediatric exclusivity. Patent status cannot be inferred from the grant date alone because term adjustment, terminal disclaimers, pediatric extensions, and litigation settlements can change the effective commercial timeline.[4]

How strong is the Myrbetriq formulation patent estate?

The formulation estate is strongest where claims connect a specific polymer system or release profile to measurable performance. Broad claims covering any extended-release mirabegron tablet are more vulnerable to prior-art and enablement challenges than narrow claims tied to defined polymer ratios, dissolution limits, or manufacturing parameters.

An ANDA applicant should conduct separate analyses for:

• Claim scope covering polyethylene oxide matrices
• Claims covering hypromellose or mixed-polymer systems
• Tablet coating claims
• Granule or suspension claims
• Pediatric dosing and administration claims
• Salt, polymorph, particle-size, or solid-state claims
• Manufacturing-process claims

Excipient substitution alone does not guarantee freedom to operate. A patent claim may cover the finished dosage form by functional performance rather than by a named excipient.

When does Myrbetriq lose exclusivity?

Myrbetriq exclusivity depends on the interaction of FDA regulatory exclusivity, Orange Book-listed patents, pediatric extension, and any settlement agreements with generic applicants. The product is not eligible for biosimilar competition because mirabegron is a chemically synthesized small molecule, not a biologic.

The main entry pathways are:

• Paragraph IV certification against listed patents
• Paragraph III certification with launch after patent expiry
• A settlement agreement providing a negotiated entry date
• Authorized-generic supply or licensing
• A non-infringing formulation supported by a different patent position

FDA approval of a generic does not necessarily mean immediate commercial launch. The applicant may remain blocked by a listed patent, a settlement restriction, a 180-day exclusivity period, manufacturing readiness, or commercial contracting.

Which companies are challenging Myrbetriq?

Public generic competition should be assessed through FDA ANDA records, Paragraph IV litigation dockets, Orange Book certifications, and court settlements. Patent challenges may be filed by multiple applicants and may not result in a near-term launch.

The relevant competitive groups include:

• Large generic manufacturers with established extended-release capabilities
• Indian manufacturers with high-volume oral-solid-dose plants
• Specialty generic companies targeting controlled-release products
• API manufacturers seeking vertical integration
• Contract manufacturers offering private-label or authorized-generic supply

The most credible competitors will have experience with hydrophilic matrix tablets, dissolution-sensitive products, and FDA inspection requirements. A company with only immediate-release tablet capability may face material development risk.

What excipient opportunities exist in Myrbetriq Granules?

Myrbetriq Granules expands the commercial opportunity beyond tablet replication. Pediatric oral suspension creates demand for excipients that improve palatability, redispersibility, dose uniformity, and storage stability.

Taste masking

Mirabegron taste masking is a major development issue for pediatric use. Potential approaches include:

• Polymer coating of drug particles
• Ion-exchange resin complexes
• Lipid or wax barriers
• pH-modified granules
• Sweetener and flavor systems
• Microencapsulation

The taste-masking system must not produce dose dumping or materially change mirabegron exposure. A coating that delays drug release in the stomach may compromise bioequivalence even if the product is acceptable to pediatric patients.

Suspension stability

A commercial pediatric product should maintain uniform dosing after reconstitution and shaking. Useful excipient functions include:

• Suspending agents
• Wetting agents
• Buffers
• Preservatives, where permitted
• Antimicrobial systems
• Density modifiers
• Anti-caking agents

The product must remain physically stable through the labeled in-use period. Sedimentation, caking, foaming, nozzle blockage, and inaccurate dosing can create regulatory and liability exposure.

Pediatric administration systems

Commercial differentiation can come from the delivery device rather than from the drug formulation. Oral syringes with dose markings, bottle adapters, child-resistant closures, and low-residue containers can reduce administration errors and support hospital and specialty-pharmacy adoption.

What manufacturing and intellectual-property barriers affect excipient suppliers?

The manufacturing barrier is moderate for tablets and higher for pediatric granules. Extended-release matrix tablets require control of blend uniformity, compression, polymer hydration, dissolution, and scale-up behavior. Granules add coating, suspension, reconstitution, and packaging complexity.

Excipient suppliers may create defensible positions through:

• Proprietary high-viscosity polymer grades
• Controlled particle-size distributions
• Co-processed excipients for direct compression
• Taste-masking coatings
• Stabilized pediatric suspension systems
• Drug-excipient compatibility data
• Platform know-how for scale-up and dissolution control

The strongest commercial position is usually created by combining excipient supply with formulation development support. A commodity supplier is easier to replace. A supplier whose material is embedded in the approved control strategy has greater switching costs.

How does Myrbetriq compare with competing overactive-bladder drugs?

Myrbetriq competes with antimuscarinic products such as oxybutynin, solifenacin, tolterodine, and fesoterodine. It also competes with combination regimens, including mirabegron plus solifenacin in markets where combination products are available.

Product class	Main formulation opportunity	Commercial constraint
Mirabegron extended-release	Matrix-tablet replication, pediatric granules	Patent and bioequivalence risk
Oxybutynin extended-release	Matrix or osmotic systems	Mature generic competition
Solifenacin	Immediate- or modified-release tablets	Lower formulation complexity
Tolterodine	Extended-release capsules or tablets	Established generic supply
Mirabegron-solifenacin combinations	Fixed-dose extended release	Higher formulation and regulatory complexity

Myrbetriq's once-daily dosing and non-antimuscarinic mechanism support continued demand, but the product competes in a price-sensitive category after generic entry. Excipient differentiation must therefore reduce manufacturing cost, improve supply reliability, or enable a clinically meaningful pediatric or administration advantage.

What commercial opportunities exist for excipient manufacturers?

The most attractive opportunities are:

1. Pharmaceutical-grade polyethylene oxide and hypromellose for controlled-release matrices.
2. Co-processed direct-compression systems that improve tablet uniformity.
3. Taste-masking platforms for mirabegron granules.
4. Suspension stabilizers and preservative systems for pediatric products.
5. Film-coating systems that reduce processing time and moisture sensitivity.
6. Oral dosing devices integrated into pediatric packaging.
7. Technical services supporting dissolution matching and scale-up.
8. Dual-source excipient strategies for generic manufacturers seeking supply continuity.

Revenue exposure for the originator is concentrated in mirabegron product sales, while excipient suppliers gain revenue from every approved generic, private-label product, or contract-manufactured equivalent that uses their materials. The addressable market is therefore linked to the number of ANDA approvals and the speed of generic substitution, not only to originator sales.

What is the FDA regulatory status of Myrbetriq?

FDA approved Myrbetriq tablets for adults with overactive bladder and later expanded its use in specified pediatric populations. FDA also approved Myrbetriq Granules for oral suspension for pediatric patients with neurogenic detrusor overactivity.[1,5]

For a generic extended-release tablet, the regulatory burden includes:

• ANDA pharmaceutical-equivalence review
• Comparative dissolution
• In vivo bioequivalence, where required
• Fed and fasted assessments
• Stability data
• Manufacturing-process validation
• Container-closure evaluation
• Labeling consistency
• Risk assessment for excipient differences

For a pediatric suspension or granule product, the applicant may face additional questions on dose uniformity, reconstitution, in-use stability, palatability, device performance, and administration instructions.

What generic launch risks exist for Myrbetriq?

The principal launch risks are:

• Unexpected Orange Book patent listings
• Paragraph IV litigation
• Settlement-based launch restrictions
• Failure to match the reference dissolution profile
• Polymer variability at commercial scale
• Food-effect differences
• Pediatric granule stability failures
• API supply constraints
• FDA manufacturing observations
• Price erosion after multiple generic entrants

The formulation risk is manageable for a well-resourced generic manufacturer, but the product is less attractive than a simple immediate-release tablet. The best-positioned entrant will combine patent counsel, controlled-release formulation expertise, qualified polymer suppliers, and an established commercial channel.

Key Takeaways

• Myrbetriq uses a mirabegron extended-release platform centered on hydrophilic polymer matrix technology.
• Polyethylene oxide, hypromellose, coating materials, lubricants, and glidants are the most commercially relevant excipient groups.
• Generic developers can change excipients, but they must preserve pharmaceutical performance and bioequivalence.
• Pediatric granules create separate opportunities in taste masking, suspension stability, packaging, and oral dosing devices.
• Mirabegron is a small molecule, so generic competition proceeds through the ANDA pathway rather than biosimilar approval.
• The controlling US patent and exclusivity position should be evaluated through the current FDA Orange Book and litigation record.
• Excipient suppliers have the strongest position when they provide both materials and formulation-support data.
• The main technical barrier is matching extended-release dissolution at manufacturing scale without infringing formulation claims.

FAQs

Is polyethylene oxide essential to a generic Myrbetriq formulation?

No. A generic applicant may use another polymer or polymer combination if the product satisfies FDA quality and bioequivalence requirements and does not infringe relevant patents.

Can a generic company sell mirabegron granules instead of tablets?

Potentially, but a granule product may require a different regulatory strategy and must address pediatric dosing, taste, suspension stability, reconstitution, and bioequivalence requirements.

Are Myrbetriq excipients patentable?

Yes. Excipient combinations can be protected when they are part of a novel formulation, release profile, manufacturing process, or performance-defined dosage form. The excipient itself is often not proprietary.

Does Myrbetriq have biosimilar competition?

No. Mirabegron is a synthetic small molecule. Competition is expected through generic ANDA products, not biosimilar applications.

Which excipient has the highest commercial value in Myrbetriq replication?

High-consistency controlled-release polymers, particularly polyethylene oxide and hypromellose grades, are the most strategically important for the tablet. For pediatric products, taste-masking and suspension-stabilization systems may have greater differentiation value.

References

1. U.S. Food and Drug Administration. (2024). Myrbetriq (mirabegron) prescribing information. Astellas Pharma US, Inc.

2. U.S. Food and Drug Administration. (2020). ANDAs for certain highly purified synthetic peptides: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Patent No. 8,129,343. (2012). Benzene derivatives. U.S. Patent and Trademark Office. Assignee: Astellas Pharma Inc.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2021). FDA approves new formulation of Myrbetriq for pediatric patients with neurogenic detrusor overactivity. U.S. Department of Health and Human Services.